ライフサイエンスコーパス: atrial fibrillation

1 (coronary heart disease, heart failure, and atrial fibrillation).

2 (41%; age 78 +/- 11 years, 18% men, 32% with atrial fibrillation).

3 , coronary heart disease, heart failure, and atrial fibrillation).

4 for focusing the framework: hypertension and atrial fibrillation.

5 fibrosis is a major contributor to sustained atrial fibrillation.

6 myocardial remodeling that paves the way of atrial fibrillation.

7 bservational associations between height and atrial fibrillation.

8 tion of cardioembolic stroke attributable to atrial fibrillation.

9 en shown to contribute to the development of atrial fibrillation.

10 of stroke/systemic embolism in patients with atrial fibrillation.

11 with increased incidence of ventricular and atrial fibrillation.

12 at may result in an antiarrhythmic effect on atrial fibrillation.

13 f traditional cardiovascular risk factors on atrial fibrillation.

14 luded 56,587 ESKD hemodialysis patients with atrial fibrillation.

15 weight has also been associated with risk of atrial fibrillation.

16 for NPV triggers in patients with paroxysmal atrial fibrillation.

17 herosclerotic CVD, stroke, heart failure and atrial fibrillation.

18 ngle pulse IRE PV isolation in patients with atrial fibrillation.

19 t (LGE) with atrial voltage in patients with atrial fibrillation.

20 d electrogram abnormalities in patients with atrial fibrillation.

21 eter ablation is considered in patients with atrial fibrillation.

22 thmia recurrence in patients with paroxysmal atrial fibrillation.

23 m channel TASK-1 as a therapeutic target for atrial fibrillation.

24 -mediated cognitive decline in patients with atrial fibrillation.

25 f atrial abnormalities including the risk of atrial fibrillation.

26 rnerstone of the management of patients with atrial fibrillation.

27 atheter ablation in patients with persistent atrial fibrillation.

28 e patients admitted with ischemic stroke and atrial fibrillation.

29 eight may offer new targets for treatment of atrial fibrillation.

30 lmonary vein (PV) isolation in patients with atrial fibrillation.

31 scular risk patients, and anticoagulation in atrial fibrillation.

32 Alcohol abstinence in drinkers with atrial fibrillation.

33 is likely a positive causal risk factor for atrial fibrillation.

34 biomarker release, myocardial fibrosis, and atrial fibrillation.

35 ho underwent catheter ablation of paroxysmal atrial fibrillation.

36 hether height has a causal effect on risk of atrial fibrillation.

37 ined significantly associated with new-onset atrial fibrillation.

38 ial fibrosis and increases susceptibility to atrial fibrillation.

39 t of persistent and long-standing persistent atrial fibrillation.

40 he range of kidney function in patients with atrial fibrillation.

41 offer therapeutic avenues for patients with atrial fibrillation.

42 or variants associated with ECG measures and atrial fibrillation.

43 irthweight and a large biobank-based GWAS of atrial fibrillation.

44 mproved anticoagulation use in patients with atrial fibrillation.

45 c slices from 358 patients with nonrecurrent atrial fibrillation (1-3 mm interspace per slice, 20-200

46 y dose use were: 1.69 (95% CI 1.54-1.85) for atrial fibrillation, 1.75 (95% CI 1.56-1.97) for heart f

47 ical trials for obstructive sleep apnoea and atrial fibrillation(16).

48 , 253 myocardial infarction, 180 strokes, 65 atrial fibrillation, 29 revascularizations, and 246 CVD

49 ng to rhythm (atrial fibrillation 8.03:1; no atrial fibrillation 5.75:1) and with age, renal function

50 47.3+/-17 years old, having vagal paroxysmal atrial fibrillation 58 (70%) or neurocardiogenic syncope

51 %), previous heart failure (10% versus 19%), atrial fibrillation (6% versus 10%), and chronic obstruc

52 ed in 13,426 (15.3%) people, including 6,013 atrial fibrillation, 7,727 heart failure, and 2,809 acut

53 tio varied considerably according to rhythm (atrial fibrillation 8.03:1; no atrial fibrillation 5.75:

54 In persistent atrial fibrillation, a positive correlation was found be

55 luded treatment with antiarrhythmic drugs or atrial fibrillation ablation after randomization.

56 o-pay threshold of $100 000 per QALY gained, atrial fibrillation ablation was found to be economicall

57 alone in an unselected population undergoing atrial fibrillation ablation with low fibrosis burden.

58 as an important predictor of recurrence post-atrial fibrillation ablation.

59 pressure (BP) control or anticoagulation in atrial fibrillation (AF) (Trial 2).

60 CLOSE-guided atrial fibrillation (AF) ablation is based on contiguous

61 rform transesophageal echocardiograms before atrial fibrillation (AF) ablation procedures in patients

62 Atrial fibrillation (AF) adversely impacts health-relate

63 Outcomes of postoperative atrial fibrillation (AF) after noncardiac surgery are no

64 2Y12 inhibitor) in patients with nonvalvular atrial fibrillation (AF) after percutaneous coronary int

65 The aim was to evaluate, in patients with atrial fibrillation (AF) and acute ischemic stroke, the

66 Atrial fibrillation (AF) and atrial flutter (AFL) are as

67 Obesity is an independent risk factor for atrial fibrillation (AF) and is associated with a higher

68 ic diseases, the incidence and prevalence of atrial fibrillation (AF) are rising, justifying the term

69 Atrial fibrillation (AF) can be maintained by localized

70 Risk prediction models for atrial fibrillation (AF) do not give information about w

71 Catheter ablation of persistent atrial fibrillation (AF) has limited success.

72 Scientific research on atrial fibrosis in atrial fibrillation (AF) has mainly focused on quantitat

73 ation and focal breakthroughs in humans with atrial fibrillation (AF) have been recently demonstrated

74 ischaemic and haemorrhagic complications in atrial fibrillation (AF) have been studied, but there ar

75 It is difficult to noninvasively phenotype atrial fibrillation (AF) in a way that reflects clinical

76 the only anti-arrhythmic agents approved for atrial fibrillation (AF) in patients with reduced left v

77 The optimal timing of catheter ablation for atrial fibrillation (AF) in reference to the time of dia

78 Growing prevalence of atrial fibrillation (AF) in the ageing population and it

79 tional block in one limb, is associated with atrial fibrillation (AF) induction.

80 Atrial fibrillation (AF) is a highly prevalent cardiac a

81 Atrial fibrillation (AF) is a major risk factor for stro

82 Atrial fibrillation (AF) is an increasingly prevalent ar

83 Atrial fibrillation (AF) is associated with a risk of is

84 Atrial fibrillation (AF) is associated with increased ri

85 A very late recurrence (VLR) of atrial fibrillation (AF) is considered present when the

86 nd treatment of sleep apnea in patients with atrial fibrillation (AF) is critical.

87 n with direct oral anticoagulants (DOACs) in atrial fibrillation (AF) is dependent on adherence and p

88 Susceptibility to atrial fibrillation (AF) is determined by well-recognize

89 The incidence of atrial fibrillation (AF) is higher in patients with diab

90 Atrial fibrillation (AF) is the most common arrhythmia a

91 Atrial fibrillation (AF) is the most common clinical arr

92 Atrial fibrillation (AF) is the most common heart rhythm

93 Atrial fibrillation (AF) is the most common sustained ar

94 Atrial fibrillation (AF) is the most common sustained ca

95 Atrial fibrillation (AF) is the most common sustained ca

96 Emerging evidence suggests that atrial fibrillation (AF) may be associated with an incre

97 protein biomarkers associated with incident atrial fibrillation (AF) may improve the understanding o

98 Atrial fibrillation (AF) may occur after an acute precip

99 Atrial fibrillation (AF) often arises from structural ab

100 umulation associates with the progression of atrial fibrillation (AF) pathology and adversely affects

101 Asthma and atrial fibrillation (AF) share an underlying inflammator

102 ve a lower prevalence of clinically detected atrial fibrillation (AF) than whites, despite a higher p

103 lation) trial randomized 2,204 patients with atrial fibrillation (AF) to catheter ablation or drug th

104 for persistent and long-standing persistent atrial fibrillation (AF) treatment led to the developmen

105 Catheter ablation for atrial fibrillation (AF) using point-by-point radiofrequ

106 ocessing algorithm to identify patients with atrial fibrillation (AF) using text alone.

107 imated that over 46 million individuals have atrial fibrillation (AF) worldwide, and the incidence an

108 ed with vast data sources, the management of atrial fibrillation (AF), a common chronic disease with

109 e, obesity, tobacco use, hypertension (HTN), atrial fibrillation (AF), and chronic obstructive pulmon

110 icient to treat all patients with persistent atrial fibrillation (AF), and effective adjunctive ablat

111 fective treatment strategy for patients with atrial fibrillation (AF), but many experience AF recurre

112 ed obesity as an independent risk factor for atrial fibrillation (AF), but the underlying pathophysio

113 associated with an increased propensity for atrial fibrillation (AF), causing higher mortality than

114 mic heart disease (IHD), heart failure (HF), atrial fibrillation (AF), stroke, peripheral artery dise

115 ered over a 100 genetic loci associated with atrial fibrillation (AF), the most common arrhythmia.

116 Atrial fibrillation (AF), the most common sustained card

117 vitamin K antagonists (VKAs) for preventing atrial fibrillation (AF)-related stroke.

118 increasingly used treatment for symptomatic atrial fibrillation (AF).

119 in several well-characterized goat models of atrial fibrillation (AF).

120 and bleeding in a cohort with cirrhosis and atrial fibrillation (AF).

121 reflex/functional bradyarrhythmias and vagal atrial fibrillation (AF).

122 nherited predisposition may increase risk of atrial fibrillation (AF).

123 hortened or prolonged PWD is associated with atrial fibrillation (AF).

124 tly been shown to detect concurrent episodic atrial fibrillation (AF).

125 es mellitus (T2DM) have an increased risk of atrial fibrillation (AF).

126 e dysfunction (SND) is often associated with atrial fibrillation (AF).

127 nd arterial thromboembolism in patients with atrial fibrillation (AF).

128 ied hundreds of genetic loci associated with atrial fibrillation (AF).

129 Ablation is a widely used therapy for atrial fibrillation (AF); however, arrhythmia recurrence

130 safety outcomes for patients with new onset atrial fibrillation after cardiac surgery who are treate

131 y end points were freedom from recurrence of atrial fibrillation (after a 2-week "blanking period") a

132 In patients with atrial fibrillation and a bioprosthetic mitral valve, ri

133 rmalized ratio, 2.0 to 3.0) in patients with atrial fibrillation and a bioprosthetic mitral valve.

134 aneous Coronary Intervention), patients with atrial fibrillation and a recent acute coronary syndrome

135 Aspirin vs Aspirin Placebo in Patients With Atrial Fibrillation and Acute Coronary Syndrome and/or P

136 es than usual care among patients with early atrial fibrillation and cardiovascular conditions.

137 In an exploratory analysis of patients with atrial fibrillation and CHA(2)DS(2)-VASc score of 2, hig

138 variables such as hypertension, cholesterol, atrial fibrillation and changes in kidney function, left

139 Among patients with atrial fibrillation and CrCl 25 to 30 mL/min, apixaban c

140 Atrial fibrillation and delirium are common consequences

141 34 569 new users of oral anticoagulants with atrial fibrillation and estimated glomerular filtration

142 Among patients with paroxysmal atrial fibrillation and hypertension, renal denervation

143 f the left atrial appendage in patients with atrial fibrillation and permanent contraindications for

144 ents for early-onset coronary heart disease, atrial fibrillation and prostate cancer.

145 In AUGUSTUS, 4614 patients with atrial fibrillation and recent acute coronary syndrome o

146 estigated for the treatment of patients with atrial fibrillation and rheumatic heart disease, for the

147 Among patients with permanent atrial fibrillation and symptoms of heart failure treate

148 etomidine reduces the incidence of new-onset atrial fibrillation and the incidence of delirium.

149 ng, sleep, cerebrovascular disease, frailty, atrial fibrillation and vitamin C).

150 se (CVD), including coronary artery disease, atrial fibrillation, and heart failure, was more prevale

151 d, differs between patients with and without atrial fibrillation, and increases substantially with in

152 sing the 3-incision technique, no history of atrial fibrillation, and ischemic cause.

153 carotid endarterectomy, anticoagulation for atrial fibrillation, and patent foramen ovale closure.

154 updated hypertension, cholesterol, diabetes, atrial fibrillation, and primary prevention guidelines.

155 nt of endocarditis, oral anticoagulation for atrial fibrillation, and prosthetic valves are vital the

156 15.50), followed by coronary heart disease, atrial fibrillation, and stroke.

157 improve screening and primary prevention of atrial fibrillation, and whether biological pathways inv

158 d systolic hypertension, with versus without atrial fibrillation, and with versus without diabetes me

159 mise in improving outcomes in heart failure, atrial fibrillation, and, in preclinical studies, certai

160 Ischemic strokes related to atrial fibrillation are highly prevalent, presenting wit

161 ause stroke among hemodialysis patients with atrial fibrillation are partially mediated by lower use

162 Four cases of (paroxysmal) atrial fibrillation are presented, two cases of sepsis a

163 t of CCM signals (including in subjects with atrial fibrillation) as the 3-lead system, is equally sa

164 y index, history of hypertension, history of atrial fibrillation, AS-related symptoms, left ventricul

165 tly increased the likelihood of freedom from atrial fibrillation at 12 months.

166 ared apixaban with warfarin in patients with atrial fibrillation at an increased risk of stroke.

167 ed recurrence of any atrial tachyarrhythmia (atrial fibrillation, atrial flutter, or atrial tachycard

168 fety database using MedDRA preferred terms ("atrial fibrillation," "atrial flutter").

169 her arrhythmias, including bradyarrhythmias, atrial fibrillation/atrial flutter, atrial tachycardia,

170 lysis including age, male gender, paroxysmal atrial fibrillation, basal QTc values, basal heart rate

171 and demonstrates CAD-independent effects for atrial fibrillation, body mass index, and hypertension.

172 oblems, including venous thromboembolism and atrial fibrillation, both of which are treated with anti

173 ination over age and sex in type 2 diabetes, atrial fibrillation, breast cancer and prostate cancer,

174 (after a 2-week "blanking period") and total atrial fibrillation burden (proportion of time in atrial

175 ded freedom from symptomatic arrhythmia, the atrial fibrillation burden, and quality of life.

176 In patients with atrial fibrillation but lower CHA(2)DS(2)-VASc scores, t

177 t and Aging Research in Genomic Epidemiology Atrial Fibrillation), C(2)HEST (coronary artery disease

178 arrhythmias related to inflammation such as atrial fibrillation can also be expected, in addition to

179 ardiomyopathy characterized by high rates of atrial fibrillation, conduction disease, advanced heart

180 schemic heart disease, aortic valve disease, atrial fibrillation, congenital heart disease, various c

181 tients aged 60 years or older with permanent atrial fibrillation (defined as no plan to restore sinus

182 prolonged cardiac monitoring for subclinical atrial fibrillation detection through smartphone applica

183 we randomly assigned patients who had early atrial fibrillation (diagnosed <=1 year before enrollmen

184 on trunk, patent foramen ovale, and time for atrial fibrillation diagnosis to the ablation, we found

185 ables to clinical factors improved new-onset atrial fibrillation discrimination in a multivariable lo

186 edical history, and development of new-onset atrial fibrillation during the first four days of ICU ad

187 l fibrillation burden (proportion of time in atrial fibrillation) during 6 months of follow-up.

188 Improvements in Atrial Fibrillation Effect on Quality-of-Life scores wer

189 evolutionize the management of patients with atrial fibrillation: electroporation (pulsed-field ablat

190 associated with heart failure, ischemia, and atrial fibrillation, enhance Na(+) influx, generating a

191 n Addition to Catheter Ablation to Eliminate Atrial Fibrillation (ERADICATE-AF) trial was an investig

192 porating age, sex, body mass index, existing atrial fibrillation, existing heart failure, diabetes me

193 nts 18 to 80 years of age who had paroxysmal atrial fibrillation for which they had not previously re

194 0,258 patients with four arrhythmia classes: atrial fibrillation, general supraventricular tachycardi

195 on (LAAO) to prevent stroke in patients with atrial fibrillation has been evaluated in 2 randomized t

196 mmonly used to reduce thromboembolic risk in atrial fibrillation, have been incriminated as probable

197 ing cerebral SVD with large vessel atheroma, atrial fibrillation, heart failure, and heart valve dise

198 (hazard ratio [HR], 5.6 [95% CI, 2.3-13.5]), atrial fibrillation (HR, 2.6 [95% CI, 1.7-3.5]), and lef

199 es Registry for Better Informed Treatment of Atrial Fibrillation II Registry from 2013 to 2016, 741 u

200 gle-nucleotide polymorphisms associated with atrial fibrillation in ambulatory studies using a Sequen

201 have demonstrated that catheter ablation for atrial fibrillation in patients with heart failure with

202 er week and who had paroxysmal or persistent atrial fibrillation in sinus rhythm at baseline were ran

203 ow it may impact the way we currently detect Atrial Fibrillation in the general population.

204 ceptibility contributes to risk of new-onset atrial fibrillation in the ICU.

205 5 referral centers for catheter ablation of atrial fibrillation in the Russian Federation, Poland, a

206 e control therapy in patients with permanent atrial fibrillation, in particular those with coexisting

207 High-risk groups of patients with atrial fibrillation include patients with end-stage rena

208 mary types of genetic analyses performed for atrial fibrillation, including linkage studies, genome-w

209 econdary stroke prevention for patients with atrial fibrillation, including those with high risk of b

210 anagement of ESKD hemodialysis patients with atrial fibrillation, investigating racial/ethnic dispari

211 Atrial fibrillation is a common cardiovascular disorder,

212 artery bypass graft surgery in patients with atrial fibrillation is associated with a higher rate of

213 Atrial fibrillation is associated with multiple adverse

214 Atrial fibrillation is the most common sustained cardiac

215 gement of individuals with covert paroxysmal atrial fibrillation, is a topic of intensive research in

216 After adjusting for age, sex, type of atrial fibrillation, left atrium area, hypertension, str

217 asal heart rates, higher rates of paroxysmal atrial fibrillation, lower platelet count.

218 Myocardial fibrosis is key for atrial fibrillation maintenance.

219 cardiac electrograms during human persistent atrial fibrillation mapping (n=16).

220 In 135 centers, 2789 patients with early atrial fibrillation (median time since diagnosis, 36 day

221 The major indication was atrial fibrillation (n = 31 [60%]).

222 not undergo surgery (n=25), had a history of atrial fibrillation (n=45), or had no information on the

223 in Stroke and Other Thromboembolic Events in Atrial Fibrillation; n=18 201) compared apixaban with wa

224 Ablation System for Treatment of Paroxysmal Atrial Fibrillation; NCT03639597) in patients with parox

225 rized by a profile of electrical phenotypes (atrial fibrillation, nonsustained ventricular tachycardi

226 ssociated with electrical phenotypes such as atrial fibrillation, nonsustained ventricular tachycardi

227 become a favourable option in patients with atrial fibrillation not eligible for oral anticoagulatio

228 In non-surgical patients with atrial fibrillation, novel oral anticoagulants (NOACs) h

229 en reported, including erectile dysfunction, atrial fibrillation, obstructive sleep apnoea, osteoporo

230 Grade 3-4 atrial fibrillation occurred in one (1%) patient and gra

231 weight was associated with increased risk of atrial fibrillation (odds ratio, 1.27 [95% CI, 1.14-1.41

232 and may explain the higher vulnerability to atrial fibrillation of obese patients.

233 cs of a contemporary cohort of patients with atrial fibrillation on OAC who underwent cardiac cathete

234 medetomidine should not be infused to reduce atrial fibrillation or delirium in patients having cardi

235 defined as occurrence of postcardiac surgery atrial fibrillation or flutter of at least 30 seconds du

236 44% to 0.59%) for the background population; atrial fibrillation or flutter: 3.44% (95% CI: 3.06% to

237 In patients with atrial fibrillation or other indications for anticoagula

238 No cases of jaw osteonecrosis, atrial fibrillation, or nonhealing fractures were report

239 ciations with coronary artery disease (CAD), atrial fibrillation, or reduced left ventricular functio

240 Postoperatively, AKI was associated with atrial fibrillation (P = 0.013) and pneumonia (P = 0.005

241 in older patients (p = 0.019) and those with atrial fibrillation (p = 0.066), lower hematocrit (p = 0

242 us myocardial infarction, heart failure, and atrial fibrillation (P<0.001) and was superior and incre

243 her incidence of early de-novo postoperative atrial fibrillation (P=0.003).

244 Postoperative atrial fibrillation (pAF) after coronary artery bypass g

245 Paroxysmal atrial fibrillation (PAF) detection was higher in the IC

246 red in the intravenous immunoglobulin group (atrial fibrillation, pancreatitis, vulvar pain, chest tu

247 Patients with symptomatic drug-refractory atrial fibrillation (paroxysmal and persistent) undergoi

248 th an anticoagulation-eligible but untreated atrial fibrillation patient.

249 ort included 55 paroxysmal and 21 persistent atrial fibrillation patients undergoing either RF/PF (40

250 A total of 333 enrolled persistent atrial fibrillation patients underwent ablation.

251 coagulation percentage relative to peers for atrial fibrillation patients with elevated stroke risk (

252 Despite improvements in the management of atrial fibrillation, patients with this condition remain

253 (Pulsed Fields for Persistent Atrial Fibrillation [PersAFOne]; NCT04170621).

254 Postoperative atrial fibrillation (POAF) is a common and troublesome c

255 Closure vs. Novel Anticoagulation Agents in Atrial Fibrillation (PRAGUE-17) was a multicenter, rando

256 Closure vs. Novel Anticoagulation Agents in Atrial Fibrillation [PRAGUE-17]; NCT02426944).

257 cent structures are frequent in patient with atrial fibrillation (prevalence: 13.5%).

258 lation may be a novel therapeutic target for atrial fibrillation prevention and treatment.

259 trigger origins in patients with paroxysmal atrial fibrillation receiving catheter ablation.

260 neous coronary intervention in patients with atrial fibrillation receiving oral anticoagulation.

261 ion, there was a significantly lower rate of atrial fibrillation recurrence with catheter cryoballoon

262 End-Stage Liver Disease XI score, history of atrial fibrillation, redo surgery, and body mass index >

263 limited rhythm control to the management of atrial fibrillation-related symptoms.

264 Human patients with persistent atrial fibrillation show sixfold lower levels of myocard

265 oagulation with Factor Xa Next Generation in Atrial Fibrillation), SOLID-TIMI 52 (Stabilization of Pl

266 are also introduced for stroke prevention in atrial fibrillation (SPAF).

267 tcomes associated with catheter ablation for atrial fibrillation stratified by diagnosis-to-ablation

268 of the relationship between birthweight and atrial fibrillation, supporting the growing body of evid

269 arrhythmic Ca(2+) activities, and alleviated atrial fibrillation susceptibility in aged and alcohol-e

270 Canadian Cardiovascular Society Severity of Atrial Fibrillation symptom classification, >80% of pati

271 s is a central pathophysiological feature of atrial fibrillation that also hampers its treatment; the

272 In patients with symptomatic paroxysmal atrial fibrillation that has not responded to medication

273 Atrial fibrillation, the most common cardiac arrhythmia,

274 ulants vs. Warfarin for post Cardiac Surgery Atrial Fibrillation: The NEW-AF Trial.

275 nitial treatment for symptomatic, paroxysmal atrial fibrillation, there was a significantly lower rat

276 on; NCT03639597) in patients with paroxysmal atrial fibrillation, this LICU system was evaluated to d

277 , which showed that amongst individuals with atrial fibrillation, those with genetically lower levels

278 oagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarctio

279 ents with symptomatic, paroxysmal, untreated atrial fibrillation to undergo catheter ablation with a

280 stemic embolism in patients with nonvalvular atrial fibrillation; transcatheter aortic valve replacem

281 lp with shared decision-making in persistent atrial fibrillation treatment.

282 Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial [CABANA]; NCT00911508).

283 ation Versus Antiarrhythmic Drug Therapy for Atrial Fibrillation) trial randomized 2,204 patients wit

284 In the enrolled 52 patients with paroxysmal atrial fibrillation, ultrasound M-mode-based left atrial

285 In a real-world registry of patients with atrial fibrillation undergoing cardiac catheterization,

286 sion on short-term outcomes in patients with atrial fibrillation undergoing isolated coronary artery

287 undred thirty-four consecutive patients with atrial fibrillation undergoing radiofrequency ablation w

288 tip catheter could safely and rapidly ablate atrial fibrillation using either a combined RF/PF approa

289 nsider the impact of birthweight on incident atrial fibrillation using summary data from the Early Gr

290 opathy, hypertension, myocardial infarction, atrial fibrillation, valvular disease, and revasculariza

291 hat 15% of FIX-HF-5C2 subjects had permanent atrial fibrillation versus 0% in FIX-HF-5C.

292 The median percentage of time in atrial fibrillation was 0% (interquartile range, 0 to 0.

293 guided radiofrequency ablation of persistent atrial fibrillation was associated with a significant de

294 tide polymorphisms associated with new-onset atrial fibrillation were rs3853445 (near PITX2, p = 0.00

295 ver 70 years who had mitral valve disease or atrial fibrillation when compared with patients aged les

296 creases and prolongs spontaneous episodes of atrial fibrillation, whereas atrial-specific overexpress

297 of aspirin among patients with both CCS and atrial fibrillation who require anticoagulation.

298 tively analyzed 521 patients with paroxysmal atrial fibrillation who underwent catheter ablation of p

299 n the CASTLE-AF study (Catheter Ablation for Atrial Fibrillation With Heart Failure) population.

300 (4) ventricular tachycardia (>15 beats); (5) atrial fibrillation with rapid ventricular response; (6)